(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease

被引:37
作者
Ishizuka, S
Kurihara, N
Reddy, SV
Cornish, J
Cundy, T
Roodman, GD
机构
[1] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA
[2] Teijin Inst Biomed Res, Tokyo 1918512, Japan
[3] Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA 15261 USA
[4] Univ Auckland, Dept Med, Auckland 92019, New Zealand
关键词
D O I
10.1210/en.2004-1140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoclast ( OCL) precursors from patients with Paget's disease ( PD) and normal OCL precursors transduced with the measles virus nucleocapsid protein gene ( MVNP) are hyperresponsive to 1 alpha, 25- dihydroxyvitamin D-3 [ 1 alpha, 25-( OH) D-2(3)] and can form OCLs at physiologic concentrations of 1 alpha, 25( OH) D-2(3). This hyperresponsivity to 1 alpha, 25-( OH)(2)D-3 is due to increased expression of TATA box- associated factor II- 17, a potential coactivator of the vitamin D receptor. Hyperresponsivity to 1 alpha, 25-( OH)(2)D-3 may permit OCL formation in PD patients with low levels of 1 alpha, 25-( OH)(2)D-3 and play a role in the pathogenesis of PD. Therefore, we tested the effects of a vitamin D antagonist, ( 23S)- 25- dehydro- 1 alpha- hydroxyvitamin D-3- 26,23- lactone ( TEI- 9647), to determine its potential to inhibit the enhanced OCL formation and bone resorption seen in patients with PD. TEI- 9647, by itself, was not a vitamin D receptor agonist and did not induce OCL formation in vitro, even at 10(-6) M. However, it dose- dependently ( 10(-10) M to 10(-6) M) inhibited osteoclast formation induced by concentrations of 1 alpha, 25-( OH)(2)D-3 ( 41 pg/ ml, 10(-10) M) detected in PD patients by bone marrow cells of patients with PD and MVNP- transduced colony- forming unit- granulocyte macrophage ( CFU- GM) cells, which form pagetic- like OCL. Moreover, bone resorption by OCLs derived from MVNP- transduced CFU- GM treated with 10(-9) M 1 alpha,25-( OH)(2)D-3 was dose- dependently inhibited by TEI- 9647 ( 10(-9) M to 10(-6) M). Furthermore, 10(-7) M TEI- 9647 by itself did not cause 1 alpha, 25-( OH)(2)D-3- dependent gene expression but almost completely suppressed expression of the TATA box- associated factor II- 17 and 25- hydroxyvitamin D-3- 24-hydroxylase genes induced by 1 alpha, 25-(OH)(2)D-3 treatment of MVNP- transduced CFU- GM cells. These results demonstrate that TEI- 9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD.
引用
收藏
页码:2023 / 2030
页数:8
相关论文
共 19 条
[11]  
MILLS BG, 1984, CLIN ORTHOP RELAT R, P303
[12]   Antagonistic action of novel 1α,25-dihydroxyvitamin D3-26,23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1α,25-dihydroxyvitamin D3 [J].
Miura, D ;
Manabe, K ;
Ozono, K ;
Saito, M ;
Gao, QZ ;
Norman, AW ;
Ishizuka, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (23) :16392-16399
[13]   Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D3 and RANKL [J].
Neale, SD ;
Smith, R ;
Wass, JAH ;
Athanasou, NA .
BONE, 2000, 27 (03) :409-416
[14]   Analysis of the molecular mechanism for the antagonistic action of a novel 1α,25-dihydroxyvitamin D3 analogue toward vitamin D receptor function [J].
Ozono, K ;
Saito, M ;
Miura, D ;
Michigami, T ;
Nakajima, S ;
Ishizuka, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32376-32381
[15]  
REBEL A, 1974, NOUV PRESSE MED, V3, P1299
[16]  
Reddy SV, 1996, J BONE MINER RES, V11, P1602
[17]   Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts [J].
Reddy, SV ;
Kurihara, N ;
Menaa, C ;
Landucci, G ;
Forthal, D ;
Koop, BA ;
Windle, JJ ;
Roodman, GD .
ENDOCRINOLOGY, 2001, 142 (07) :2898-2905
[18]   BONE-MARROW MONONUCLEAR-CELLS FROM PATIENTS WITH PAGETS-DISEASE CONTAIN MEASLES-VIRUS NUCLEOCAPSID MESSENGER-RIBONUCLEIC-ACID THAT HAS MUTATIONS IN A SPECIFIC REGION OF THE SEQUENCE [J].
REDDY, SV ;
SINGER, FR ;
ROODMAN, GD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (07) :2108-2111
[19]  
SIRIS ES, 2003, PRIMER METABOLIC BON, P497